Abstract 11P
Background
Breast cancer survivors suffer from various survivorship issues, including persistent pain, sensory changes, and poor quality of life, often overlooked in traditional mortality and morbidity indicators. The study's objective was to determine whether intercostobrachial nerve (ICBN) preservation resulted in reduced chronic pain, sensory changes, and improved quality of life in breast cancer survivors.
Methods
A prospective observational study was conducted between 2018 and 2020 among 81 breast cancer patients undergoing axillary lymph node dissection and was divided into two cohorts based on the ICBN preservation or division. The patients were interviewed at 6 months with EORTC QoL Questionnaire.
Results
ICBN preserved group had statistically significant less frequent sensory changes at discharge 51.5% vs. 87.5% (p=<0.001) which improved at six months 27.3% vs. 72.7% (p=<0.001). Clinically significant pain was reduced in the ICBN preservation group 15.2% vs. 84.8% (p=<0.001). Similarly, it had significantly better scores in physical, emotional functioning domains in EORTC QoL and fewer scores in symptom scales of pain and fatigue.
Conclusions
Our study shows that preservation of the intercostobrachial nerve is associated with significantly reduced pain in the chest wall, axilla, arm, lesser sensory changes, and improved quality of life. ICBN preservation should be considered in all patients undergoing axillary dissection for breast cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
17P - Clinical, pathological complete response and prognosis characteristics of HER2-low breast cancer in neoadjuvant chemotherapy setting: A retrospective analysis
Presenter: Hui Liu
Session: Poster viewing 01
18P - Low levels of miR-18a is associated with immunosuppression and increased chemo-unresponsiveness in ER-negative tumors
Presenter: Madhumathy Nair
Session: Poster viewing 01
19P - Cardiac and lung sparing radiotherapy in breast and chest wall irradiation with surface guided radiotherapy using deep inspiratory breath hold technique
Presenter: Ravi Shankar Bellala
Session: Poster viewing 01
20P - Physician perceptions to use of trastuzumab in HER2+ breast cancer in India
Presenter: Nagendra Ramanjinappa
Session: Poster viewing 01
23P - Combination chemotherapy and hormone therapy (CHT) in patients with hormone receptor (HR) positive, HER2 negative metastatic breast cancer (MBC): A single-centre retrospective analysis
Presenter: Kripa Bajaj
Session: Poster viewing 01
24P - Outcomes of patients with HER2 positive metastatic breast cancer treated with low dose or metronomic lapatinib
Presenter: Sherin Mathew
Session: Poster viewing 01
25P - Absolute lymphocyte count as prognostic factor in patients with metastatic breast cancer: A systematic review and meta-analysis
Presenter: Dhea Hermanto
Session: Poster viewing 01
26P - Circulating osteocalcin-positive cells, as a novel biomarker for monitoring the therapeutic effects on bone metastasis
Presenter: Min Joo Kim
Session: Poster viewing 01
27P - Outcomes analysis of the effect of an educational activity on the knowledge and confidence of oncologists regarding emerging antibody drug conjugates for the treatment of breast cancer
Presenter: Nabil Dorkhom
Session: Poster viewing 01
28P - Development 68Ga trastuzumab Fab and bioevaluation by PET imaging in HER2/neu-expressing breast cancer patients
Presenter: Yogesh Rathore
Session: Poster viewing 01